Solifenacin for overactive bladder with incontinence: Symptom bother and health-related quality of life outcomes

Alan D. Garely, Vincent Lucente, Jonathan Vapnek, Neila Smith

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


BACKGROUND: Approximately one-third of patients with overactive bladder(OAB) experience incontinence, a bothersome symptom with a clear negative effect on quality of life. OBJECTIVE: To assess OAB patients' perceptions of improvements in symptom bother and quality of life after taking solifenacin under conditions reflecting day-to-day practice. METHODS: VOLT (the VESIcare Open-Label Trial) was a prospective, open-label study in patients with OAB (defined as urgency, urge urinary incontinence, daytime frequency, or nocturia for ≥3 mo) who were treated with flexibly dosed, once-daily solifenacin for 12 weeks. This study included subjects enrolled in VOLT who, at baseline, had urge incontinence and reported incontinence as their most bothersome symptom. All patients were started on solifenacin 5 mg/day; at week 4, the dosage could be increased to 10mg/day and at week 8 could be maintained or decreased back to 5 mg/day. Efficacy was assessed by 3 independent patient-reported outcomes: the Patient Perception of Bladder Condition (PPBC) scale, a visual analog scale (VAS) for assessing individual symptoms, and the Overactive Bladder Questionaire (OAB-q). RESULTS: Of the 2205 patients in the VOLT full analysis set, 1586 (71.9%) had urge incontinence at baseline, of which 582 (36.7%) reported incontinence as their most bothersome symptom. In this cohort, mean PPBC score at baseline was 4.6 (indicating moderate-to-severe problems) and at endpoint had decreased significantly to 2.9 (very minor to some minor problems; p < 0.001). At endpoint, 80.4% of patients achieved improvement in their PPBC score. These patients reported significant improvements from baseline in urinary urgency, urge incontinence, frequency, and nocturia on the VAS (p < 0.001) and all OAB-q domains (symptom severity, coping, concern, sleep, social health-related quality of life) at endpoint (p < 0.001). CONCLUSIONS: Patients reporting urge incontinence as their most bothersome OAB symptom can be expected to demonstrate significant improvements in multiple patient-related outcomes following treatment with flexibly dosed solifenacin.

Original languageEnglish
Pages (from-to)391-399
Number of pages9
JournalAnnals of Pharmacotherapy
Issue number3
StatePublished - Mar 2007


  • Incontinence
  • Overactive bladder
  • Solifenacin
  • Urgency


Dive into the research topics of 'Solifenacin for overactive bladder with incontinence: Symptom bother and health-related quality of life outcomes'. Together they form a unique fingerprint.

Cite this